A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
ITEM 1. BUSINESS In this report, “Stereotaxis”, the “Company”, “Registrant”, “we”, “us”, and “our” refer to Stereotaxis, Inc. and its wholly owned subsidiaries. GenesisX RMN, Genesis RMN®, Niobe®, Navigant®, Synchrony, SynX, Odyssey®, Odyssey Cinema™, MAGiC ™, EMAGIN, Map-iT™, QuikCAS™, Cardiodrive®, Vdrive®, Vdrive Duo™, V-CAS™, V-Loop™, V-Sono™, and NuVizion are trademarks of Stereotaxis, Inc. All other trademarks that appear in this report are the property of their respective owners. This annual report on Form 10-K, including the sections entitled “Business” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” contains forward-looking statements.
| Metric | TTM | FY2024 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|
| Revenue | 30M | 27M | 29M | 31M | 32M | 38M |
| Net Income | -24M | -25M | -1.3M | -7.3M | -12M | -7.4M |
| EPS | $-0.28 | $-0.30 | $-0.03 | $-0.32 | $-0.54 | $-0.35 |
| Free Cash Flow | 0 | -8.5M | -2.8M | -4.8M | -7.0M | -2.5M |
| ROIC | -41.7% | -321.4% | -148.0% | -43.8% | -24.2% | -22.6% |
| Gross Margin | 53.1% | 54.2% | 80.5% | 65.5% | 76.6% | 72.3% |
| Debt/Equity | 0.00 | 5.80 | 8.57 | -1.40 | -1.98 | -1.03 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -24M | -25M | -2.5M | -5.9M | -6.4M | -5.4M |
| Operating Margin | -80.1% | -91.9% | -8.4% | -19.0% | -20.0% | -14.4% |
| ROE | -377.1% | -226.1% | -100.5% | - | - | - |
| Shares Outstanding | 93M | 85M | 44M | 23M | 22M | 21M |
Stereotaxis, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 69.8%.
Stereotaxis, Inc. (STXS) has a 5-year average return on invested capital (ROIC) of -59.7%. This is below average and may indicate limited pricing power.
Stereotaxis, Inc. (STXS) has a market capitalization of $189M. It is classified as a small-cap stock.
Stereotaxis, Inc. (STXS) does not currently pay a regular dividend.
Stereotaxis, Inc. (STXS) operates in the Electromedical & Electrotherapeutic Apparatus industry, within the Healthcare sector.
Stereotaxis, Inc. (STXS) reported annual revenue of $27 million in its most recent fiscal year, based on SEC EDGAR filings.
Stereotaxis, Inc. (STXS) has a net profit margin of -94.2%. The company is currently unprofitable.
Stereotaxis, Inc. (STXS) generated $-9 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Stereotaxis, Inc. (STXS) has a debt-to-equity ratio of 5.80. This indicates higher leverage, which may increase financial risk.
Stereotaxis, Inc. (STXS) reported earnings per share (EPS) of $-0.30 in its most recent fiscal year.
Stereotaxis, Inc. (STXS) has a return on equity (ROE) of -226.1%. A negative ROE may indicate losses or negative equity.
Stereotaxis, Inc. (STXS) has a 5-year average gross margin of 69.8%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 10 years of financial data for Stereotaxis, Inc. (STXS), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Stereotaxis, Inc. (STXS) has a book value per share of $0.07, based on its most recent annual SEC filing.